Programmed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Pembrolizumab (Keytruda; Merck Sharp & Dohme) is a humanized IgG4 monoclonal antibody used in cancer immunotherapy. It targets the programmed cell death-1 (PD-1) receptor, which is important in maintaining self-tolerance. However, immune checkpoint blockade is associated with a risk for immune-related adverse events (irAEs) potentially affecting the endocrine organs. Type 1 diabetes mellitus is a rare irAE of PD-1 inhibitors, occurring in 0.2% of cases.

Related collections

Author and article information

Journal

Title: The Journal of Clinical Endocrinology & Metabolism

Publisher: The Endocrine Society

ISSN (Print): 0021-972X

ISSN (Electronic): 1945-7197

Publication date Created: September 2018

Publication date Created: September 01 2018

Publication date Created: June 27 2018

Publication date Other: September 2018

Publication date (Print): September 01 2018

Publication date (Electronic): June 27 2018

Volume: 103

Issue: 9

Pages: 3144-3154

Affiliations

[1 ]Department of Endocrinology, Diabetology & Metabolism, Antwerp University Hospital, Edegem, Belgium

[2 ]Department of Endocrinology-Nephrology, Algemeen Ziekenhuis Klina Hospital, Brasschaat, Belgium

[3 ]Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

[4 ]Department of Oncology, Antwerp University Hospital, Edegem, Belgium

[5 ]Diabetes Research Center, Brussels Free University, Brussels, Belgium

Article

DOI: 10.1210/jc.2018-00728

PubMed ID: 29955867

SO-VID: dc373beb-b4cd-4b50-879a-e394e319b612

History

Data availability:

Comments

Comment on this article

Cited by 98

See all cited by